Install
BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe. VIEW ALL FEATURED COMPANIES VIEW ALL FEATURED COMPANIES VIEW ALL FEATURED COMPANIES V
- 344articles · 30d
- 1+ day agolatest article
- Aug 14, 2026earliest in window
- 92%with images
- 291avg words
- Economy, Business & Finance 200
- Medical 159
- Health & Wellness 159
- Business & Industrial 146
- Finance & Business 135
- Health 74
- Science & Technology 53
- Science & Nature 34
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
TAE Life Sciences Achieves ISO 13485 Certification, Marking a Major Milestone in Quality and Regulatory Excellence
2+ day, 3+ hour ago (137+ words) Audit Concluded with Zero Findings, Underscoring the Company's Commitment to Patient Safety and Medical Device Quality A Defining Milestone for TAE Life Sciences The certification was awarded following a comprehensive audit conducted by BSI (British Standards Institution), a globally recognized…...
Takeda’s long-term R&D head announces exit after major pipeline reorganization
2+ day, 12+ hour ago (499+ words) iStock, Agdekon Media Visuals Takeda’s R&D chief Andy Plump will say good-bye to the drugmaker, with a retirement slated for next summer. “Andy has made the personal decision to retire in June 2027 after more than 10 years leading Takeda’s global…...
Retension Pharmaceuticals Appoints LeAnne Bloedon, M.S., RD, as EVP of Clinical Development and Operations, and Kevin Schutz, PharmD, as VP Regulatory Affairs
2+ day, 15+ hour ago (140+ words) Statistics cookies help us to understand how visitors interact with websites by collecting and reporting information anonymously. Marketing cookies allow us to display more relevant ads that are engaging for our users and thereby, they are more valuable for publishers…...
Encoded raises $275M series F for Dravet syndrome gene therapy
2+ day, 17+ hour ago (423+ words) Encoded Therapeutics has closed a $275 million series F round to help advance its investigational Dravet syndrome therapy into pivotal development. Much of the proceeds will go toward Encoded’s lead asset ETX101, according to a Wednesday release. The therapy is being tested…...
Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism
3+ day, 16+ hour ago (169+ words) Initiation of Phase 3 registrational study on track by year-end; topline results expected in late 2028; U.S. FDA approval and launch anticipated in 2030 The Company expects XP-8121 peak net revenue potential of $1 to $3 billion Capstone — Pediatric Study Touchstone — Special Population Study Clinical Perspective…...
Caspian launches with $50M, Lilly support to advance disease-modifying diabetes bet
3+ day, 19+ hour ago (197+ words) Caspian Therapeutics has arrived on the biopharma scene, bringing with it $50 million in starting funds, a potentially disease-modifying answer for diabetes and the backing of the industry’s biggest player in metabolic disease, Eli Lilly. The funding push was led by…...
Novartis’ $12B Avidity acquisition hits Phase 3 speedbump as dystrophy drug disappoints
4+ day, 18+ hour ago (522+ words) Novartis’ investigational antibody-oligonucleotide conjugate del-desiran—one of the pharma’s main bounties from its $12 billion buyout of Avidity Biosciences last year—failed a late-stage study of myotonic dystrophy type 1, potentially giving competitors the opportunity to take the lead in this market....
Moonwalk pulls in $70M to take fat-targeting RNAi obesity candidate to clinic
4+ day, 18+ hour ago (373+ words) Eli Lilly–backed obesity drugmaker Moonwalk Biosciences has raised $70 million in a Series B funding round to support its efforts to advance a long-lasting RNAi-based treatment to clinical trials. Moonwalk’s lead obesity candidate, MW101, has demonstrated weight loss and fat reduction…...
Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference
1+ week, 3+ day ago (248+ words) BioSpace Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced…...
Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential
1+ week, 3+ day ago (284+ words) Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody Teva will hold an investor call and live webcast today,Wednesday, September 2, 2026, at 8:00 a.m. ET to discuss these data. Additional analyses from the ongoing Phase 2a study…...